The funding will be used to ramp-up US and international sales and marketing for the FirmGrip catheter. The patent pending Flexicath FirmGrip is said to be designed to meet the market needs for the largest segment of intravenous (IV) catheterizations, those lasting up to 29 days.
The company has said that its FirmGrip may save the need for a sterile sheet by enclosing the catheter in a special self-contained package that permits insertion without removing the catheter from the sterilized coating sleeve until the procedure is complete and the catheter is in the vein.
According to the company, the system makes the IV insertion process faster and less expensive, and allows any member of the medical team – paramedics, nurses, and physicians – to insert the catheter.
Rick Zitelman, principal of The Zitelman Group, said: We are very pleased to be helping Flexicath bring this important new healthcare technology to the US market, and we congratulate them on receiving the FDA clearance for this purpose.